- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Cognition Therapeutics, Inc.: Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB) | 30 | GlobeNewswire (Europe) | - End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer's Disease Scheduled - - Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies - PURCHASE, N.Y., June 25... ► Artikel lesen | |
| Fr | COGNITION THERAPEUTICS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 09.06. | H.C. Wainwright maintains $3 target on Cognition Therapeutics stock | 1 | Investing.com | ||
| COGNITION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 03.06. | Cognition Therapeutics, Inc.: Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies | 1 | GlobeNewswire (USA) | ||
| 02.06. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | Cognition Therapeutics, Inc.: Cognition Therapeutics Releases New Episode of "Conversations" Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies | 1 | GlobeNewswire (USA) | ||
| 09.05. | Cognition Therapeutics Presents Preclinical Data On Zervimesine, Stock Down | 1 | RTTNews | ||
| 09.05. | Cognition Therapeutics, Inc.: Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health | 5 | GlobeNewswire (USA) | ||
| 08.05. | Cognition Therapeutics GAAP EPS of -$0.14 misses by $0.04 | 5 | Seeking Alpha | ||
| 08.05. | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy | 70 | GlobeNewswire (Europe) | Zervimesine treatment slowed the rate of GA lesion growth by 28.6% compared to placebo Observed GA lesion area was reduced by 28.2% at 18 months compared to placebo Dry AMD results validate zervimesine's... ► Artikel lesen | |
| 07.05. | COGNITION THERAPEUTICS INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.05. | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update | 216 | GlobeNewswire (Europe) | - End-of-Phase 2 meeting with FDA requested for Alzheimer's disease - - Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC - - Two posters at ARVO describe zervimesine's... ► Artikel lesen | |
| 07.05. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 6 | SEC Filings | ||
| 01.04. | Cognition Therapeutics, Inc.: Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes | 122 | GlobeNewswire (Europe) | PURCHASE, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative... ► Artikel lesen | |
| 25.03. | Cognition Therapeutics wird Ergebnisse der Alzheimer-Studie präsentieren | 3 | Investing.com Deutsch | ||
| 25.03. | Cognition Therapeutics to present Alzheimer's study results | 1 | Investing.com | ||
| 25.03. | Cognition Therapeutics, Inc.: Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025 | 1 | GlobeNewswire (USA) | ||
| 24.03. | Cognition Therapeutics stock price target cut to $5 at H.C. Wainwright | 1 | Investing.com | ||
| 20.03. | COGNITION THERAPEUTICS INC - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 20.03. | COGNITION THERAPEUTICS INC Loss At -$33.97 Mln In Full Year | 4 | RTTNews |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 89,70 | -0,11 % | Biotech Report: Biontech rutschen ab; Sektor an der Wall Street leichter | (shareribs.com) Frankfurt / New York 23.06.2025 - Biotech-Aktien zeigen sich im deutschen Handel überwiegend leichter. Unter anderem sacken Biontech kräftig ab. Auch an der Wall Street bewegt sich der... ► Artikel lesen | |
| CUREVAC | 4,650 | +0,09 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
| AMGEN | 238,40 | -0,87 % | ROUNDUP/Aktien New York Schluss: Gewinne - 'Iran-Angriff eine Gesichtswahrung' | NEW YORK (dpa-AFX) - Der Nahost-Krieg hat am Montag die Richtung an den US-Börsen bestimmt. Die wichtigsten US-Indizes legten am Ende kräftig zu und erreichten kurz vor dem Handelsschluss Tageshöchststände.... ► Artikel lesen | |
| NOVAVAX | 5,536 | -0,34 % | Novavax Sees Sanofi Vaccine Pact as Model for Future Deals, Some Going Beyond Infectious Disease | ||
| BIOGEN | 109,10 | -0,14 % | Biogen Inc.: Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results | Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,143 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| BIOXXMED | 0,420 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| OCUGEN | 0,897 | +0,97 % | Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen | |
| MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von Bauchspeicheldrüsenkrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,270 | +0,13 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 | VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 8,208 | +0,15 % | CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? | ||
| BIO-GATE | 0,970 | -2,51 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,472 | +0,21 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen |
Das Unternehmen COGNITION THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,301 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COGNITION THERAPEUTICS INC finden Sie auf Wallstreet Online.